Search for: "BARR LABORATORIES, INC."
Results 1 - 20 of 71
Sorted by Relevance | Sort by Date
9 Aug 9:59 pm
Common Sense, Perhaps, But Whose? By Kevin E. Noonan -- The Supreme Court in KSR International Co. v. Teleflex Inc. established a standard (such as it is) of "common sense" in
evaluating whether an invention is obvious. If the Court had been careful to follow the statute, it might have stressed more carefully that the answer to the question "whose common
sense" must be the person of ordinary skill in the art. Perhaps it was the contempt they obviously felt for the invention at issue -- an ...
6 Mar, 2008 9:53 pm
By Kevin E. Noonan -- On Monday, the U.S. District Court for the District of New Jersey (Judge Peter G. Sheridan, presiding) found after a bench trial on all issues that Bayer's U.S.
Patent 6,787,531 was invalid for obviousness. In doing so, the Court's decision illustrated anew the uncertainties that...
17 Aug 8:01 am
... that it was reviewing the ADDERALL XR patent litigation settlement agreement between Shire and Barr Laboratories, Inc.
('Barr'). On June 22, 2007, the Company received a civil investigative demand requesting that it provides information ... and manufacturing
know how. But there is something else that might be important to note. In the Adderall IR settlement, Barr agreed to provide manufacturing
backup for products that might emerge from the development agreement. Right now, Shire manufactures the ...
17 Aug 8:01 am
... that it was reviewing the ADDERALL XR patent litigation settlement agreement between Shire and Barr Laboratories, Inc.
('Barr'). On June 22, 2007, the Company received a civil investigative demand requesting that it provides information ... and manufacturing
know how. But there is something else that might be important to note. In the Adderall IR settlement, Barr agreed to provide manufacturing
backup for products that might emerge from the development agreement. Right now, Shire manufactures the ...
27 Dec, 2006 7:18 am
... , Barr issued a press release yesterday, December 26, 2006, as reported at PR Newswire that stated: Barr Laboratories, Inc., a subsidiary of Barr Pharmaceuticals, Inc. (NYSE: BRL), today
confirmed that it is seeking approval from the U.S. Food & Drug ... the 50 mg and 100 mg capsule strengths. On December 13, 2006, Celgene confirmed it had received notification of
Barr's ANDA on file with the FDA containing a Paragraph IV certification for Thalomid Capsules, 200 mg. Celgene indicated that it ...
22 Jul, 2008 3:36 am
... Ltd. and Barr Pharmaceuticals, Inc. announced late last week that they have entered into an agreement by which Teva will acquire
Barr for $7.46 billion plus the assumption of $1.5 billion in debt. The transaction is expected to close by the end of ... approval.
Barr Pharmaceuticals, Inc., a holding company, operates through subsidiaries Barr
Laboratories, Inc., Duramed Pharmaceuticals, Inc., and PLIVA d.d. and its subsidiaries. Teva is the leading generic pharmaceutical company worldwide, and...
12 Jul, 2007 1:36 pm
... reported by PRNewswire today, July 12, 2007, and appearing at PharmaLive: Barr Pharmaceuticals, Inc. today confirmed that its
subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patent listed by Boehringer Ingelheim in connection with
... 2007, Boehringer Ingelheim, et al., filed suit in the U.S. District Court of Delaware to prevent Barr from proceeding with the
commercialization of its product. This action formally initiates the patent challenge process under the Hatch-Waxman Act ...
17 Jan, 2007 1:23 pm
... December 13, 2006, Celgene Corp. announced that it had received notification from Barr Laboratories, Inc. that
Barr had filed an ANDA for generic thalidomide, 200 mg tablets ... name Thalomid. On December 26, 2006, Celgene announced that it had received
notification of Barr's ANDA for the 50 and 100 mg strengths of Thalomid. The ANDAs contained ... ENL recurrence, according to the Orange Book
use codes. Assuming that Celgene received Barr's notice on December 13, 2006, for the 200 mg tablets, then Celgene ...
5 Mar, 2008 8:20 pm
PR Newswire reported today, March 5, 2008: Barr Pharmaceuticals, Inc. (NYSE: BRL) today announced that its wholly-owned subsidiary,
Duramed Pharmaceuticals, Inc., has filed suit against Watson Pharmaceuticals (NYSE: WPI) and its subsidiary, Watson Laboratories, Inc., for infringement of the
patent protecting Duramed's SEASONIQUE(R) extended-cycle oral contraceptive product. The Company's SEASONIQUE Patent No. 7,320, ...
9 Oct 9:11 am
... Inc. and Teva Pharmaceutical Industries Ltd. (patent infringement) 9/16: Dorman Products Inc. v. Gates Corporation (trademark infringement) 9/16: Fair Isaac
Corporation v. ... : US Philips Corporation v. Samsung Electronics Company Ltd. and Samsung Electronics America Inc. (patent infringement) 9/18: Research Foundation of State
University of New York, New ... v. PLIVA-HRVATSKA d.o.o, PLIVA d.d., Barr Laboratories Inc., Barr Pharmaceuticals Inc., Barr Pharmaceuticals, LLC, et al. (patent infringement)
24 Jul 12:18 pm
... from the sales representative, the rep should be included in the suit. The generic of Yaz, Ocella, is manufactured by Barr
Laboratories, Inc. Lawsuits against Barr should include Teva Pharmaceutical Industries Ltd., which acquired Barr in late 2008. ... Claims, if applicable Punitive Damages The misrepresentation counts are particularly viable here in light of the FDA's castigation of
Barr over their Yaz ads. Bayer recently started a new advertising campaign to correct earlier bad marketing, ...
12 Jun 10:49 am
... One Bank, N.A., fka Capital One Bank, et al., v. Commissioner of Revenue of Massachusetts ; Geoffrey, Inc., v. Commission of Revenue Massachusetts Issue: Whether the Supreme
Judicial Court of Massachusetts violated the Commerce Clause by permitting ... of the underlying patent challenge? Opinion below (Federal Circuit) Petition for certiorari Brief in
opposition of respondents Barr Laboratories, Inc. Brief in opposition of respondents Bayer AG and Bayer Corp Petitioner's reply
Brief amici curiae of ...
1 Aug, 2006 8:38 am
... am surprised there is only one story about modafinil (according to a Google News search). According to MarketWatch: Mylan Laboratories Inc. (MYL) said Monday that the
Federal Trade Commission is investigating the company's patent-litigation settlement related to ... . Cephalon also entered separate agreements with Teva Pharmaceuticals USA Inc.
(TEVA), Ranbaxy Pharmaceuticals Inc. and Barr Laboratories Inc. (BRL). According to Mylan Laboratories' quarterly
report filed Friday with the Securities and ...
11 Oct 9:04 pm
... in the District Court of Delaware • Plaintiff: The Medicines Company • Defendants: PLIVA-HRVATSKA d.o.o.; PLIVA d.d.; Barr
Laboratories Inc.; Barr Pharmaceuticals Inc.; Barr Pharmaceuticals, LLC; Teva
Pharmaceuticals Industries Ltd.; Teva Pharmaceuticals USA Inc. Infringement of U.S. Patent No. 7,582,727 ("Pharmaceutical Formulations of Bivalirudin and Process of Making the
Same," issued September 1, 2009) following a...
13 Nov, 2007 11:18 pm
... called on Congress to take action, says such settlements could cost American consumers billions of dollars. (...) In one of those cases, Barr Laboratories Inc. abandoned its successful challenge to AstraZeneca PLC's patent for the breast cancer drug tamoxifen. In exchange,
Barr received a $21 million payment and entered an agreement with AstraZeneca under which Barr sold
generic tamoxifen provided by AstraZeneca. Consumers filed a ...
14 Feb, 2008 7:09 am
... , the agency contends.According to the Commission, by late 2005, generic competition to Provigil appeared imminent. Several years earlier, on the first day permitted by regulation,
four companies - Teva Pharmaceuticals USA, Inc. (Teva), Ranbaxy Pharmaceuticals, Inc. (Ranbaxy), Mylan Pharmaceuticals Inc. (Mylan), and Barr Laboratories, Inc. (Barr) - submitted applications with the U.S. Food and Drug Administration
(FDA) to market their ...
27 Oct, 2008 1:37 am
... Report: Each week we will report briefly on recently filed biotech and pharma cases, and a few interesting cases will be selected for periodic monitoring.Endo Pharmaceuticals
Inc. et al. v. Barr Laboratories Inc.1:08-cv-00782; filed October 20, 2008 in the District ... 5,958,456 (same title,
issued September 28, 1999) following a Paragraph IV certification as part of Barr's filing of an ANDA to manufacture a generic version of
Endo's Opana® ER (oxymorphone hydrochloride, used to ...
12 Feb 10:42 am
... they argue gets them around the preemption ruling in Riegel v. Medtronic, Inc., 128 S. Ct. 999 (2008). If Levine comes down the right ... several adjacent identical opinions
with the same name); Little v. Depuy Motech, Inc., 2000 WL 1519962, at *7 (S.D. Cal. June 13, 2000); ... .D.N.C. July 21, 1998); United States v. Barr Laboratories, Inc., 812 F. Supp. 485, 486 (D.N.J. 1993 ... wanting based upon the vagueness of the statutory standard. Baraukas v. Danek
Medical, Inc., 2000 WL 223508, at *4 n.2 (M.D.N.C ...
21 Nov, 2007 6:35 am
... of a lawsuit that led to a 2005 federal appeals court ruling upholding the legality of the payments. In that case, Barr Laboratories
Inc. accepted a $21 million payment to abandon its successful challenge to AstraZeneca PLC's patent for the breast cancer drug tamoxifen. In addition to the financial payout,
AstraZeneca also agreed to let Barr sell tamoxifen provided by AstraZeneca. See the full article here. See also this related article from the
Daytona Beach News ...
6 Jul 4:54 pm
... an antitrust lawsuti against brand-name drugmaker, Bayer AG, and its U.S. subsidiary, Bayer Corp., and a generic manufacturer, Barr
Laboratories, Inc., along with Barr's business partners who challenged Bayer, leading to the "reverse payments" deal. A panel of
the Second Circuit on April 6 asked the Justice Department to file a brief on "whether settlement of patent infringement lawsuits violates the federal antitrust laws when ...
Search on: Blawgs.FM | BlawgSearch Google Co-op |
Blawg.com | Bloglines | Feedster | Google Blog Search |
Technorati | Google | MSN | Yahoo!